Treatments for rare diseases face a uniquely challenging pricing and reimbursement environment. To be successful, companies need a specialised approach:
- Pricing strategies need to be transparent, value-based, and defensible to all rare disease stakeholders
- Communication of product value must reflect complex mechanisms of disease, heterogeneous patient burden, and innovative science
- Ever-changing pricing and reimbursement pathways require up-to-date knowledge of international processes and engagement with policy makers to ensure a sustainable business model for continued investment and innovation in treatments for rare diseases.
Tap into our rare knowledge to support your rare disease portfolio.
Use our interactive services map to learn more about how Dolon can provide strategic market access support for your product and portfolio. Or read more about our three key service areas: